Tenaya Therapeutics Appoints New CMO, Director
Ticker: TNYA · Form: 8-K · Filed: Sep 16, 2024
Sentiment: neutral
Topics: management-change, board-appointment, officer-appointment
TL;DR
Tenaya brings in a new CMO and adds a director to the board.
AI Summary
Tenaya Therapeutics, Inc. announced on September 12, 2024, the appointment of Dr. Faraz Ali as Chief Medical Officer and the election of Ms. Jennifer L. D. Fox to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are included in the filing.
Why It Matters
The appointment of a new Chief Medical Officer and a board member can signal strategic shifts or new directions for the company's drug development and governance.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- Dr. Faraz Ali (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. D. Fox (person) — Elected to Board of Directors
- September 12, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Tenaya Therapeutics?
Dr. Faraz Ali has been appointed as the new Chief Medical Officer for Tenaya Therapeutics.
Who has been elected to the Board of Directors at Tenaya Therapeutics?
Ms. Jennifer L. D. Fox has been elected to the Board of Directors at Tenaya Therapeutics.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 12, 2024.
What is the principal executive office address for Tenaya Therapeutics?
The address of Tenaya Therapeutics' Principal Executive Offices is 171 Oyster Point Boulevard, Suite 500, South San Francisco, California, 94080.
What other items are disclosed in this 8-K filing besides officer and director changes?
The filing also discloses compensatory arrangements of certain officers and financial statements and exhibits.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-09-16 16:05:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
Filing Documents
- tnya-20240912.htm (8-K) — 52KB
- tnya-ex10_1.htm (EX-10.1) — 430KB
- 0000950170-24-106817.txt ( ) — 661KB
- tnya-20240912.xsd (EX-101.SCH) — 25KB
- tnya-20240912_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: September 16, 2024